RNAi-mediated knockdown of AURKB and EGFR shows enhanced therapeutic efficacy in prostate tumor regression

Gene Therapy

Volumn 17, Issue 3, 2010, Pages 352-359

  Addepalli, M K ^a   Ray, K B ^a   Kumar, B ^a   Ramnath, R L ^a   Chile, S ^a   Rao, H ^a  

^a RELIANCE LIFE SCIENCES PVT LTD   (India)

Author keywords

AURKB; EGFR; Prostate cancer; RNAi

Indexed keywords

AURORA B KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; SMALL INTERFERING RNA; SMALL INTERFERING RNA 26; SMALL INTERFERING RNA 28; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GENE THERAPY; CANCER INHIBITION; CANCER REGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; RNA INTERFERENCE;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; GENE KNOCKDOWN TECHNIQUES; GENE THERAPY; HUMANS; INTERFERONS; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; MUS MUSCULUS;

EID: 77949423993     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.155     Document Type: Article

References (26)

1. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nature 2009; 6: 76-85.
2. Lorenzo G, Tortora G, Armiento FP, Rosa G, Staibano S, Autorino R et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002; 8: 3438-3444.
3. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 17: 1654-1663.
4. Pihan GA, Wallace J, Zhou Y, Doxsey SJ. Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res 2003; 63: 1398-1404.
5. Fu J, Bian M, Jiang Q, Zhang C. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007; 5: 1-10.
6. Lee ECY, Frolov A, Li R, Ayala G, Greenberg NM. Targeting aurora kinases for the treatment of prostate cancer. Cancer Res 2006; 66: 4996-5002.
7. Tatsuka M, Katayama H, Ota T, Tanaka T, Odashima S, Suzuki F et al. Multinuclearity and increased ploidy caused by over-expression of the aurora-and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. Cancer Res 1998; 58: 4811-4816.
8. Chieffi P, Cozzolino L, Kisslinger A, Libertini S, Staibano S, Mansueto G et al. Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation. Prostate 2006; 66: 326-333.
9. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002; 8: 3438-3444.
10. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6: 4885-4892.
11. Marciniak DJ, Rishi AK, Sarkar FH, Majumdar APN. Epidermal growth factor receptor-related peptide inhibits growth of PC-3 prostate cancer cells. Mol Cancer Ther 2004; 3: 1615-1621.
12. Zhang Y, Zhang Y-F, Bryant J, Charles A, Boado RJ, Pardridge WM. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res 2004; 10: 3667-3677.
13. Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 2007; 13: 3682-3688.
14. Woodburn JR. The epidermal growth factor receptor and it's inhibition in cancer therapy. Pharmacol Ther 1999; 82: 241-250.
15. Nozawa H, Tadakuma T, Ono T, Sato M, Hiroi S, Masumoto K et al. Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma. Cancer Sci 2006; 97: 1115-1124.
16. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growthfactor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
17. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 2003; 95: 851-867.
18. Ritter CA, Arteago CL. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol 2003; 30: 3-11.
19. Weihua Z, Tsan R, Huang W-C, Wu Q, Chiu C-H, Fidler IJ et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 2008; 13: 385-393.
20. Broxterman HJ, Georgopapadakou NH. Anticancer therapeutics: 'addictive' targets, multi-targeted drugs, new drug combinations. Drug Resist Updat 2005; 8: 183-197.
21. Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007; 7: 107-117.
22. Zimmermann M, Zouhair A, Azria D, Ozsahin M. The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol 2006; 1: 11.
23. Kent LL, Hull-Campbell NE, Lau T, Wu JC, Thomson SA, Nori M. Characterization of novel inhibitors of cyclin-dependent kinases. Biochem Biophys Res Commun 1999; 260: 768-774.
24. Zhao L, Wientjes MG, Au JL-S. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 2004; 10: 7994-8004.
25. Srikantan V, Valladres M, Rhim JS, Moul JW, Srivastava S. HEPSIN inhibits cell growth/invasion in prostate cancer cells. Cancer Res 2002; 62: 6812-6816.
26. Mastronardi L, Guiducci A, Puzzilli F. Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas. BMC Cancer 2001; 1: 12.